Herasight
Herasight provides polygenic genetic screening for embryos created through IVF, combining DNA from embryo biopsies with family medical history to estimate the risk of thousands of conditions, from single-gene disorders to common diseases such as cancer, heart disease and diabetes.
- Category
- Bio and Healthcare
- Fund
- NZVC II
- Website
- www.herasight.com
What Herasight does
Herasight's ImputePGTA method genotypes embryos and computes polygenic scores at higher accuracy than earlier approaches, giving prospective parents information to help rank embryos for implantation.
The secret behind Herasight
An embryo biopsy yields very little DNA, which is what held polygenic screening back. ImputePGTA reconstructs the missing genotype accurately enough to score thousands of conditions from that tiny sample, which is the step that moved polygenic prediction from research into a clinical decision.
Why NZVC invested in Herasight
We backed Herasight because polygenic prediction has matured to the point where it can meaningfully inform one of the most consequential decisions a family makes, and few teams have the statistical genetics depth to do it well. The founders combine rigorous research with a clear clinical product, and they publish their methods rather than hide behind marketing. IVF volumes are rising worldwide, and accurate embryo screening sits at the center of that growth.
Herasight in the press
- NPR asked whether parents should screen embryos for specific traitsNPR · 6 May 2026
- SynBioBeta described how Herasight's embryo screening worksSynBioBeta · 9 April 2026
- MIT Technology Review examined the ethics of screening embryosMIT Technology Review · 16 October 2025
- Popular Mechanics questioned the science behind predicting IQ before birthPopular Mechanics (via Yahoo News) · 7 August 2025